Senzime (SEZI) Life Science Summit 2025 summary

Industry context and medical need

• Paralytic drugs are used in anesthesia for about 100 million patients annually, requiring precise monitoring to avoid complications.

• Traditional monitoring methods have high variability, leading to frequent dosing errors and early patient awakening.

• Complications from improper dosing include partial paralysis post-surgery and increased risk of adverse events.

Technological innovation and product overview

• Developed a non-invasive nerve monitoring system (TetraGraph) with 99.7% accuracy, improving dosing precision.

• System includes a monitor and disposable sensors, now present in about 5,000 operating rooms and used on nearly a million patients.

• Technology reduces drug costs by up to 70% and eliminates complications from incorrect dosing.

Market position and growth

• Company has grown from $10 million to $100 million in revenue since 2021, with 80% growth in the first nine months of the current year.

• U.S. is the main market, accounting for about 70% of business, with rapid expansion in sensor and monitor deliveries.

• Achieved a 92% win rate in clinical evaluations and secured major contracts, including with the U.S. Department of Defense.